By far the most common cause of recurrent debilitating headaches is migraine. More than eight million Britons – three quarters of them women – suffer migraines. Migraine headaches are often severe enough to stop us doing what we want to do, and are typically accompanied by other features such as nausea, or sensitivity to lights, noises, smells, or movement. About a quarter of people with migraine experience an aura – typically flashing lights or blind spots in their vision, lasting up to 30 minutes – usually before the headache comes, but sometimes on its own without any other symptoms at all.
The condition affects more people than diabetes, asthma and epilepsy combined and is the sixth most common cause of disability in the world. Patients make lifestyle changes, take painkillers, and are prescribed drugs including beta blockers, antidepressants and anticonvulsant drugs. Tablets called triptans relieve symptoms but over time these can cause headaches themselves.
If chronic migraine does not respond to at least three drug treatments, patients may be offered jabs of the muscle-freezing drug Botox, because of its nerve-blocking effects, but this can involve 31 separate injections per treatment and has to be done in a specialist clinic.
Fremanezumab is among a new wave of drugs which targets a certain protein – in this case, calcitonin gene-related peptide (CGRP), which is responsible for the pain and nausea associated with a migraine. CGRP causes blood vessels intertwined with nerve endings in the head to swell up. Fremanezumab, which must be given by injection either every month or three months, depending on dose, contains an antibody that blocks that process.